English
Zenitva Group posted total net sales of 6,796.6 million CZK, up 5.5% from 6,441.2 million CZK in the first half of 2006. This increase in sales was the result of an 8.7% increase in pharmaceutical sales.
In Poland, sales grew by 11.6% to 988.8 million CZK, while in Slovakia sales increased by 17.1% to 1,079.1 million CZK. Zentiva recorded 13.4% sales growth in Russia to 601.6 million CZK, whereas sales to other markets advanced by 24.3% to 536.4 million CZK. Zentiva"s Czech sales decreased by 5.6% to 2,226.5 million CZK, due to pressure on prices.
Romania, Zentiva"s second largest market in terms of sales, has benefited from the launch of a growing number of the Company"s internationally recognized brands. In the first half of 2007 Zentiva"s sales in Romania increased by 21.3% to CZK 1,330.2 million. In local currency terms the overall growth in sales in the first half of 2007 was 14.2%. During this period the brands of the former Sicomed contributed CZK 890.5 million to our sales in Romania, 66.9% of the total.
In the second quarter of 2007, Zentiva"s Romanian sales grew by 16.1% to CZK 673.0 million. Promoted brands accounted for 61.3% of Romanian sales in the first half of 2007, this compares with 54.0% in the first half of 2006.
Zentiva launched 4 new products in the Romanian market in the first half of 2007 including the CVS drugs Zenra, Lindaxa, and Amyx, and the oral contraceptive Chloe. Zentiva received one new marketing authorization in the first half of 2007.
Euro
Dolar SUA
Franc elveţian
Liră sterlină
Gram de aur
